Sign in to myUHN Patient Portal

Clinical Trials Search Results

 

 

366247507549/22/2017 7:47:45 PMThe breast MRI is used in the preoperative scenario to evaluate the extension of a newly diagnosed breast cancer and to screen the contralateral breast STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:47:45 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366228507449/22/2017 7:47:36 PMA Prototype Tri-modal Imaging Device for Breast Cancer pilot study will recruit 10 breast cancer patients undergoing breast conserving surgery at Princess Margaret STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:47:36 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366249402539/22/2017 7:47:18 PMincluding a synchronous contralateral breast cancer (Note Patients found to have a contralateral breast cancer on study imaging following STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:47:18 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366206217939/22/2017 7:42:00 PMwidespread acceptance for use in breast reconstruction and other areas and has the potential to provide support to the breast implant without tissue expansion in a STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:42:00 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366203574359/22/2017 7:42:53 PMALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging but is not specific enough to detect a difference across all breast tumor types STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:42:53 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366155574449/22/2017 7:43:05 PM2. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of Benign breast disease, LCIS or DCIS of contralateral breast is allowed STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:43:05 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366192575109/22/2017 7:44:16 PMHER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Women (≥18 years of age) with metastatic breast cancer not amenable to curative STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:44:16 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366085225629/22/2017 7:48:16 PMWith Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:48:16 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366097422349/22/2017 7:48:14 PMActivity of GSK525762 in Combination With Fulvestrant in Subjects With ER+ Breast Cancer in women with advanced or metastatic ER+ breast cancer, who have disease that has STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:48:14 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
366238575269/22/2017 7:44:31 PM15-20% of early breast cancers have high levels of a protein called HER2 which is that, in women receiving treatment for breast cancer, heart edema detected by MRI at STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca9/22/2017 7:44:31 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js

~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js

Last reviewed:
Last modified: 6/16/2017 6:07 AM